193 related articles for article (PubMed ID: 18058605)
1. 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer.
Freudenberg LS; Jentzen W; Marlowe RJ; Koska WW; Luster M; Bockisch A
Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):690-3. PubMed ID: 18058605
[TBL] [Abstract][Full Text] [Related]
2. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
[TBL] [Abstract][Full Text] [Related]
3. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.
Freudenberg LS; Jentzen W; Görges R; Petrich T; Marlowe RJ; Knust J; Bockisch A
Nuklearmedizin; 2007; 46(4):121-8. PubMed ID: 17690789
[TBL] [Abstract][Full Text] [Related]
4. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons.
Freudenberg LS; Jentzen W; Petrich T; Frömke C; Marlowe RJ; Heusner T; Brandau W; Knapp WH; Bockisch A
Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2267-76. PubMed ID: 20661558
[TBL] [Abstract][Full Text] [Related]
5. Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
Wierts R; Brans B; Havekes B; Kemerink GJ; Halders SG; Schaper NN; Backes WH; Mottaghy FM; Jentzen W
J Nucl Med; 2016 Jul; 57(7):1027-32. PubMed ID: 26917706
[TBL] [Abstract][Full Text] [Related]
6. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
7. High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases.
Ruhlmann M; Jentzen W; Ruhlmann V; Pettinato C; Rossi G; Binse I; Bockisch A; Rosenbaum-Krumme S
J Nucl Med; 2016 Sep; 57(9):1339-42. PubMed ID: 27151981
[TBL] [Abstract][Full Text] [Related]
8. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging.
Jentzen W; Hoppenbrouwers J; van Leeuwen P; van der Velden D; van de Kolk R; Poeppel TD; Nagarajah J; Brandau W; Bockisch A; Rosenbaum-Krumme S
J Nucl Med; 2014 Nov; 55(11):1759-65. PubMed ID: 25332440
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
[TBL] [Abstract][Full Text] [Related]
10. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.
Hartung-Knemeyer V; Nagarajah J; Jentzen W; Ruhlmann M; Freudenberg LS; Stahl AR; Bockisch A; Rosenbaum-Krumme SJ
Ann Nucl Med; 2012 Nov; 26(9):723-9. PubMed ID: 22802008
[TBL] [Abstract][Full Text] [Related]
11. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
[TBL] [Abstract][Full Text] [Related]
12. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
Med Phys; 2016 Oct; 43(10):5279-5287. PubMed ID: 28105713
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck.
Nagarajah J; Jentzen W; Hartung V; Rosenbaum-Krumme S; Mikat C; Heusner TA; Antoch G; Bockisch A; Stahl A
Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1862-8. PubMed ID: 21739331
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I.
Pettinato C; Monari F; Nanni C; Allegri V; Marcatili S; Civollani S; Cima S; Spezi E; Mazzarotto R; Fanti S
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):509-14. PubMed ID: 23358403
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer.
Capoccetti F; Criscuoli B; Rossi G; Ferretti F; Manni C; Brianzoni E
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):536-45. PubMed ID: 19910907
[TBL] [Abstract][Full Text] [Related]
16. One size does not fit all: the merit of absorbed doses to the blood in 131I therapy for differentiated thyroid carcinoma.
Fatholahi L; Tabeie F; Pashazadeh AM; Javadi H; Assadi M; Asli IN
Health Phys; 2015 Jan; 108(1):53-8. PubMed ID: 25437520
[TBL] [Abstract][Full Text] [Related]
17. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
Med Phys; 2016 Oct; 43(10):5279. PubMed ID: 27782699
[TBL] [Abstract][Full Text] [Related]
18. 124I PET Assessment of Response of Bone Metastases to Initial Radioiodine Treatment of Differentiated Thyroid Cancer.
Jentzen W; Verschure F; van Zon A; van de Kolk R; Wierts R; Schmitz J; Bockisch A; Binse I
J Nucl Med; 2016 Oct; 57(10):1499-1504. PubMed ID: 27199362
[TBL] [Abstract][Full Text] [Related]
19. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software.
Kolbert KS; Pentlow KS; Pearson JR; Sheikh A; Finn RD; Humm JL; Larson SM
J Nucl Med; 2007 Jan; 48(1):143-9. PubMed ID: 17204711
[TBL] [Abstract][Full Text] [Related]
20. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
